- Moderna stock surged approximately 177% on August 19 after positive Phase 3 melanoma vaccine trial results
- Rothschild & Co downgrades MRNA citing overvaluation with $81 price target
Quotes
“overexuberant reaction”
“considerably overvalued”
Moderna Shares Double on Cancer Vaccine